The use of mAbs, such as adalimumab, primarily used for inflammatory bowel disease and certain autoimmune diseases, and siltuximab, an interleukin-6 (IL-6) inhibitor employed in the treatment of Castleman’s disease, illustrates the principle of modulating inflammatory pathways exacerbated by SnCs [42,44]. This evidence concerns the gene IL6 and inflammatory bowel disease.